Abraham Weizman
Overview
Explore the profile of Abraham Weizman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
590
Citations
7063
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Poyurovsky M, Weizman A
J Clin Psychopharmacol
. 2024 May;
44(4):432-433.
PMID: 38695727
No abstract available.
12.
Michaelovsky E, Carmel M, Gothelf D, Weizman A
World J Biol Psychiatry
. 2024 Mar;
25(4):242-254.
PMID: 38493364
Objectives: 22q11.2 deletion is the most prominent risk factor for schizophrenia (SZ). The aim of the present study was to identify unique transcriptome profile for 22q11.2 deletion syndrome (DS)-related SZ-spectrum...
13.
Israel A, Merzon E, Krone B, Faraone S, Green I, Golan Cohen A, et al.
J Atten Disord
. 2024 Jan;
28(5):677-685.
PMID: 38281128
Objective: We examined the association between the number, magnitude, and frequency of febrile episodes during the 0 to 4 years of life and subsequent diagnosis of ADHD. Methods: This population-based...
14.
Cortese S, Purper-Ouakil D, Apter A, Arango C, Baeza I, Banaschewski T, et al.
Lancet Psychiatry
. 2023 Dec;
11(2):143-154.
PMID: 38071998
Psychopharmacological treatment is an important component of the multimodal intervention approach to treating mental health conditions in children and adolescents. Currently, there are many unmet needs but also opportunities, alongside...
15.
Merzon E, Israel A, Krone B, Medvejer S, Cohen S, Green I, et al.
J Atten Disord
. 2023 Dec;
28(5):669-676.
PMID: 38069539
Objective: There is growing evidence of involvement of inflammatory mechanisms in ADHD. Previous studies found significantly higher rates of ADHD among children with FMF. The present study examined the rate...
16.
Merzon E, Magen E, Ashkenazi S, Weizman A, Manor I, Krone B, et al.
Nutrients
. 2023 Dec;
15(23).
PMID: 38068806
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency, impacting 4.9% of the population and more prevalent in Mediterranean communities, is a common enzymopathy with potential relevance to Attention Deficit/Hyperactivity Disorder (ADHD). This study...
17.
Bilaus B, Turchinski N, Ahdoot H, Gavish R, Shany O, Maayan R, et al.
J Addict Med
. 2023 Oct;
17(5):551-556.
PMID: 37788608
Objectives: Individuals with polysubstance use disorder (pSUD) exhibit vulnerability to relapse even after prolonged abstinence, with rehabilitation efforts achieving limited success. Previous studies highlighted dehydroepiandrosterone (DHEA) as a putative therapeutic...
18.
Uziel O, Dickstein H, Beery E, Lewis Y, Loewenthal R, Uziel E, et al.
Nutrients
. 2023 Jun;
15(11).
PMID: 37299559
Physiological and psychological distress may accelerate cellular aging, manifested by shortening of telomere length (TL). The present study focused on TL shortening in anorexia nervosa (AN), an illness combining physiological...
19.
Poyurovsky M, Weizman A
J Clin Psychopharmacol
. 2023 May;
43(4):381-382.
PMID: 37235507
No abstract available.
20.
Alamon C, Davila B, Garcia M, Nievas S, Dagrosa M, Thorp S, et al.
Mol Pharm
. 2023 Apr;
20(5):2702-2713.
PMID: 37013916
Glioblastoma (GBM), as the most central nervous system (CNS) intractable disease, has spoiled millions of lives due to its high mortality. Even though several efforts have been made, the existing...